N-azetidin-3-yl-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide trifluoroacetic acid | 1351989-61-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-azetidin-3-yl-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide trifluoroacetic acid
• 英文别名: N-Azetidin-3-yl-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide TFA salt；N-(azetidin-3-yl)-2-[[1-methyl-5-(trifluoromethyl)indazol-3-yl]amino]acetamide;2,2,2-trifluoroacetic acid
• CAS: 1351989-61-1
• 化学式: C₂HF₃O₂*C₁₄H₁₆F₃N₅O
• 分子量: 441.333
• InChiKey: CIEFJFMQWOLOJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.73
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  108
• 氢给体数：
  4
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  N-azetidin-3-yl-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide trifluoroacetic acid 、 4-hydroxy-4-(thiazol-2-yl)cyclohexanone 生成 N-[1-(4-hydroxy-4-thiazol-2-ylcyclohexyl)azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)acetamide
  参考文献：
  名称：

  Cyclohexyl-azetidinyl antagonists of CCR2

  摘要：

  本发明涉及式(I)化合物，其中：R1、R2、X和Z如规范中所定义。本发明还涉及一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖症和哮喘。本发明还涉及一种通过给哺乳动物治疗有效量的至少一种式(I)化合物来抑制CCR2活性的方法。

  公开号：

  US08436023B2
• 作为产物：
  描述：

  2-氰基-1-氟-4-(三氟甲基)苯 在 sodium cyanoborohydride 、 1-羟基苯并三唑 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 异丙醇 为溶剂， 反应 10.5h， 生成 N-azetidin-3-yl-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide trifluoroacetic acid
  参考文献：
  名称：

  Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists

  摘要：

  A novel series of 4-azetidinyl-1-aryl-cyclohexanes containing indazole or benzoisoxazole moiety have been identified as potent CCR2 antagonists with high selectivity versus hERG. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.074

文献信息

• CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20110306592A1

  公开（公告）日：2011-12-15

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涵盖式（I）的化合物，其中：R1、R2、X和Z如规范中所定义。本发明还涵盖一种预防、治疗或改善综合症、障碍或疾病的方法，其中所述的综合症、障碍或疾病是II型糖尿病、肥胖症和哮喘。本发明还涵盖通过给哺乳动物施用至少一种式（I）化合物的治疗有效量来抑制CCR2活性的方法。
• Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists
  作者：Xuqing Zhang、Heather Hufnagel、Cuifen Hou、Evan Opas、Sandra McKenney、Carl Crysler、John O’Neill、Dana Johnson、Zhihua Sui

  DOI：10.1016/j.bmcl.2011.08.074

  日期：2011.10

  A novel series of 4-azetidinyl-1-aryl-cyclohexanes containing indazole or benzoisoxazole moiety have been identified as potent CCR2 antagonists with high selectivity versus hERG. (C) 2011 Elsevier Ltd. All rights reserved.
• Cyclohexyl-azetidinyl antagonists of CCR2
  申请人：Zhang Xuqing

  公开号：US08436023B2

  公开（公告）日：2013-05-07

  The present invention comprises compounds of Formula (I). wherein: R1, R2, X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涉及式(I)化合物，其中：R1、R2、X和Z如规范中所定义。本发明还涉及一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖症和哮喘。本发明还涉及一种通过给哺乳动物治疗有效量的至少一种式(I)化合物来抑制CCR2活性的方法。